![](https://static.wixstatic.com/media/2c6a64_d12abc42ab9d4b79952098cde12b243c~mv2.jpg/v1/fill/w_119,h_53,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/2c6a64_d12abc42ab9d4b79952098cde12b243c~mv2.jpg)
![everyone everywhere.png](https://static.wixstatic.com/media/2c6a64_4e180b47752440248d32ada19575ccd0~mv2.png/v1/fill/w_800,h_49,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/everyone%20everywhere.png)
Imophoron is changing the way we make vaccines, to provide the world with the next-generation of therapeutics for unmet medical needs and future threats.
Imophoron has created novel vaccines based on the ADDomer™ platform to provide protection against infectious disease wherever it affects human health across the world.
We are a pre-clinical stage company with a novel next generation nanoparticle vaccine platform called ADDomer™. ADDomer™ is a patented technology for creating highly immunogenic vaccine candidates and is a multimeric protein-based, self-assembling nanoparticle scaffold. Proof of concept data for two highly infectious diseases demonstrates potential to prevent disease and transmission. The ADDomer™ platform also has significant potential to generate therapeutic candidates to treat disease with high unmet need such us oncology.